14681
wpdmpro-template-default,single,single-wpdmpro,postid-14681,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-7.4,vc_responsive

HMG Biopharmaceuticals National Sector Proposition

09:48 05 October in
[featured_image]
Download
Download is available until [expire_date]
  • Version
  • Download 5
  • File Size 5.05 MB
  • File Count 1
  • Create Date October 5, 2021
  • Last Updated October 5, 2021

HMG Biopharmaceuticals National Sector Proposition

The UK has a vibrant and international industry benefiting from long term vision, partnership between government and the sector, and supported by a world class talent base. The UK’s biopharmaceuticals opportunities span the country. Each region’s economy is supported by a large, talented workforce, 66% of which lies outside the South East and London; world class life sciences infrastructure including lab space, science parks and manufacturing facilities, as well as incubators and accelerators in which to start up and scale up; established clinical trials networks for streamlined trial operations; and access to public and private funding.

Specialised clusters offer opportunities in high growth subsectors such as precision medicine, cell and gene therapies, vaccine manufacturing, data science and more. The UK has highlighted these High Potential Opportunities (HPOs) to increase inward investment into the UK. Information on HPOs is available on the Great Asset Library .